Blood Podcast A JAK inhibitor for CRS and ICANS prevention; ChAdOx1-platelet interactions and post-vaccination arterial thrombosis; lineage switch, an emerging mechanism of leukemia relapse
Jul 24, 2025
Discover a new JAK inhibitor showing promise in reducing complications from CAR T-cell therapy, with a focus on preventing cytokine release syndrome and neurotoxicity. Dive into a fascinating study revealing how interactions between a popular vaccine and platelets might lead to post-vaccination arterial thrombosis. Lastly, learn about the alarming phenomenon of lineage switch in leukemia relapses, which poses serious challenges after immunotherapy, underscoring the urgent need for innovative detection and treatment methods.
AI Snips
Chapters
Transcript
Episode notes
Idacitinib Prevents CAR T Toxicities
- Idacitinib, a selective JAK1 inhibitor, reduced incidence and severity of CRS and ICANS in CD19 CAR T-cell therapy.
- It was well tolerated and did not compromise the therapy's efficacy, offering a potential preventive strategy.
Study Safety Needs Expansion
- Larger randomized studies are needed to fully define idacitinib safety and compare it with other CRS prevention methods.
- Optimizing CRS prevention is critical to expand CAR T-cell therapy access and improve patient outcomes.
ChAdOx1 Binds Platelets Under Shear
- ChAdOx1 vaccine capsid binds platelet integrin alpha-2b via an RGD sequence under arterial shear.
- This novel mechanism may explain rare post-vaccination arterial thrombosis independent of VIT.